These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7365237)

  • 1. In vivo lysis of L5178Y cells in the establishment of the tumor-dormant state in DBA/2 mice.
    Wheelock EF; Weinhold KJ; Ingenito GG; Goldstein LT
    J Immunol; 1980 Apr; 124(4):1642-7. PubMed ID: 7365237
    [No Abstract]   [Full Text] [Related]  

  • 2. Phenotypic shifts in the L5178Y lymphoma population during progression of the tumor-dormant state in DBA/2 mice.
    Trainer DL; Wheelock EF
    Cancer Res; 1984 Mar; 44(3):1063-71. PubMed ID: 6607108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of L5178Y cell phenotypes isolated during progression of the tumor-dormant state in DBA2 mice.
    Trainer DL; Wheelock EF
    Cancer Res; 1984 Jul; 44(7):2897-906. PubMed ID: 6609767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced suppressor macrophage activity associated with termination of the L5178Y cell tumor-dormant state in DBA/2 mice.
    Robinson MK; Truitt GA; Okayasu T; Wheelock EF
    Cancer Res; 1983 Dec; 43(12 Pt 1):5831-6. PubMed ID: 6227383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of L5178Y cells from tumor-dormant DBA/2 mice by specific active immunotherapy.
    Marsili MA; Robinson MK; Truitt GA; Wheelock EF
    Cancer Res; 1983 Jan; 43(1):15-21. PubMed ID: 6600159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune regulation of the L5178Y murine tumor-dormant state. II. Interferon-gamma requires tumor necrosis factor to restrain tumor cell growth in peritoneal cell cultures from tumor-dormant mice.
    Suzuki Y; Liu CM; Chen LP; Ben-Nathan D; Wheelock EF
    J Immunol; 1987 Nov; 139(9):3146-52. PubMed ID: 3117888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel tumor-specific antigen(s) response observed in a syngeneic lymphoma-bearing host.
    Manson LA
    Cancer Detect Prev Suppl; 1987; 1():111-20. PubMed ID: 3121177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor selection in vivo for reduced sensitivity to natural resistance and natural antibodies.
    Chow DA
    J Natl Cancer Inst; 1984 Feb; 72(2):339-46. PubMed ID: 6582320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of lymphocyte-mediated cytotoxicity against allogeneic tumor cells by concanavalin A in vivo.
    Anaclerio A; Waterfield JD; Möller G
    J Immunol; 1974 Sep; 113(3):870-5. PubMed ID: 4413847
    [No Abstract]   [Full Text] [Related]  

  • 10. Alanine inhibits cytotoxic responses: its production by different tumor cell lines explains differences in their immunogenicity.
    Dröge W; Wehrmaker A; Eck HP
    Cancer Detect Prev; 1988; 11(3-6):151-6. PubMed ID: 3134127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapidly reversible resistance to immune lysis of L5178Y lymphoma cells in a tumor-dormant state in DBA/2 mice.
    Okayasu T; Wheelock EF
    J Natl Cancer Inst; 1986 Jun; 76(6):1199-204. PubMed ID: 3458956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantability and sensitivity to natural killer cells of aclarubicin-resistant murine lymphoma.
    Sugimoto Y; Hirakawa Y; Tanaka N; Tahara M; Sato I; Nishimura T; Suzuki H; Tanaka N
    Cancer Res; 1986 Nov; 46(11):5646-8. PubMed ID: 3463416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro cytolysis mediated by NK effectors: modification of the susceptibility of the target cell by in vivo treatment with DTIC].
    Migliorati G; Romani L; Fioretti MC
    Boll Soc Ital Biol Sper; 1981 May; 57(9):1024-30. PubMed ID: 7284118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: in vivo and in vitro effects.
    Liu CM; Suzuki Y; Chen LP; Okayasu T; Calkins CE; Wheelock EF
    Cancer Res; 1990 Mar; 50(5):1361-7. PubMed ID: 2302701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Location of tumoral antigens in L5178Y murine lymphoma cells.
    Ramos-Damián ME; Gómez-Estrada H; Hernández-Delgado J; Tapia-Arizmendi L; Feria-Velasco A
    Arch Invest Med (Mex); 1980; 11(3):425-34. PubMed ID: 7469659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Participation of soluble H-2 antigens in serological and cellular reactions].
    Pletneva TP; Kaulen DR; Khorobrykh VV; Kirkin AF; Kotomina IF
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1979; (5):24-8. PubMed ID: 88233
    [No Abstract]   [Full Text] [Related]  

  • 17. Establishment and control of the L5178Y-cell tumor dormant state in DBA/2 mice.
    Wheelock EF; Robinson MK; Truitt GA
    Cancer Metastasis Rev; 1982; 1(1):29-44. PubMed ID: 6985247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of growth of the L5178Y murine lymphoma by means of immunization with radiated L5178Y cells.
    Ramos-Damián M; Gómez-Estrada H; Acosta-Ruiz R; Díaz-Esquivel P; Vázquez-Escobosa C
    Arch Invest Med (Mex); 1982; 13(1):29-31. PubMed ID: 7065806
    [No Abstract]   [Full Text] [Related]  

  • 19. A search for target cell structures associated with susceptibility to NK cells.
    Henney CS
    Adv Exp Med Biol; 1982; 146():357-66. PubMed ID: 7102463
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytogenetic analysis of an immunogenic mutant of the L5178Y lymphoma.
    Greenberg AH; Manougian J; Ray M; Goldenberg GJ
    Acta Cytol; 1980; 24(3):232-6. PubMed ID: 6773281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.